Filing Overview
The source text is a Form 10-Q for Selecta Biosciences, Inc., not Cartesian Therapeutics, Inc. It covers the unaudited three and nine months ended September 30, 2017, filed November 7, 2017. Selecta was a clinical-stage biopharmaceutical company developing synthetic vaccine particle technology and product candidates including SEL-212, SEL-403, SELA-070, SEL-302 and SEL-313. The filing states that no product candidates had been approved or commercialized.
Financial Condition and Results
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Grant and collaboration revenue | $0.03 million | $1.05 million | $0.19 million | $5.15 million |
| Research and development expense | $9.50 million | $6.02 million | $31.54 million | $18.67 million |
| General and administrative expense | $4.38 million | $2.50 million | $13.16 million | $7.29 million |
| Loss from operations | $(13.85) million | $(7.47) million | $(44.51) million | $(20.81) million |
| Net loss | $(14.68) million | $(7.73) million | $(45.78) million | $(22.13) million |
| Net loss per share | $(0.66) | $(0.43) | $(2.31) | $(3.39) |
| Operating cash flow | Not separately provided | Not separately provided | $(39.37) million | $(21.24) million |
Revenue was immaterial relative to operating costs, resulting in deeply negative operating and net margins. The filing does not present a meaningful revenue-based margin; based on reported figures, the nine-month operating loss substantially exceeded revenue.
- Cash and cash equivalents were $72.15 million at September 30, 2017, compared with $58.66 million at December 31, 2016.
- Short-term deposits and investments were $32.24 million, producing cash, cash equivalents and short-term investments of approximately $104.4 million, including restricted cash.
- Total assets were $109.72 million and stockholders’ equity was $65.08 million.
- Accumulated deficit increased to $197.35 million from $151.58 million at year-end 2016.
- Debt was $20.95 million, net of discounts and issuance costs, with no current portion reported at September 30, 2017.
- Common shares outstanding increased to 22.12 million from 18.44 million at December 31, 2016.
Cash Flow, Debt and Liquidity
For the first nine months of 2017, operating activities used $39.37 million and investing activities used $8.21 million. Financing activities provided $60.99 million, including approximately $47.1 million of net proceeds from the June 2017 private placement, $21.0 million of term-loan proceeds, $5.0 million from an equity issuance to Spark, and proceeds from employee equity programs. These inflows more than offset $12.9 million of debt repayments and the operating cash burn.
In September 2017, Selecta replaced its prior term loan with a $21.0 million Silicon Valley Bank facility. The facility matures February 1, 2022, bears interest at prime plus 0.5%, requires interest-only payments through August 2019, and is secured by substantially all assets other than intellectual property, while imposing a negative pledge on intellectual property. It has no financial covenants but includes customary covenants, events of default and potential acceleration provisions.
Management estimated that cash, cash equivalents, short-term investments and short-term restricted cash at September 30, 2017 would fund operating and capital requirements into mid-2019. This estimate depends on assumptions regarding clinical development costs, timing and financing availability, and management stated that additional capital will be required.
Material Changes Versus the Prior Comparable Period
- Nine-month revenue declined 96% to $0.19 million, primarily because major grants wound down and the Sanofi collaboration terminated effective May 8, 2017.
- Research and development expense increased 69% to $31.54 million, driven by expanded SEL-212 Phase 2 activities, clinical development, headcount and work on additional pipeline programs.
- General and administrative expense increased 80% to $13.16 million, reflecting public-company infrastructure, professional fees, intellectual-property activity, headcount and stock compensation.
- Nine-month net loss more than doubled to $45.78 million from $22.13 million.
- The company recognized a $0.67 million loss on extinguishment of debt in 2017, with no comparable charge in 2016.
- Financing shifted from the 2016 IPO proceeds to the 2017 private placement, new term loan and strategic equity issuances.
Guidance, Outlook, Risks and Unusual Items
Management expected continued and increasing losses as it advanced SEL-212 and other clinical and preclinical programs. Selecta expected an FDA end-of-Phase 2 meeting for SEL-212 in the first half of 2018. It did not provide product-sales guidance or a forecast for profitability.
- The company had no product revenue and expected no product sales for at least several years.
- Sanofi’s termination eliminated future payments under that collaboration and required Selecta to fund any further development of returned programs.
- Spark had paid a $2.5 million milestone and exercised a right to purchase $5.0 million of common stock after quarter-end on October 31, 2017. These were subsequent events, not September 30, 2017 balance-sheet items.
- Material risks included clinical-trial failure or delay, patient-enrollment challenges, regulatory uncertainty, safety events, reliance on third-party manufacturers and CROs, dependence on 3SBio for pegsiticase, intellectual-property challenges, collaboration termination, foreign operations and the need for additional financing.
- The company held approximately $1.7 million in Russian bank accounts, including $1.6 million of cash and cash equivalents, and did not hedge foreign-currency exposure.
- The filing reported no material legal proceedings and no off-balance-sheet arrangements.
- Management concluded that disclosure controls and procedures were effective as of September 30, 2017, with no material changes in internal control over financial reporting during the quarter.
Investor Verification Priorities
- Verify the issuer identity: the supplied filing is for Selecta Biosciences, Inc., whereas the request identifies Cartesian Therapeutics, Inc.
- Reconcile the reported liquidity runway through mid-2019 with subsequent clinical spending, financing, debt service and any later corporate transactions.
- Review SEL-212 clinical data, regulatory interactions and the status of the anticipated FDA meeting.
- Assess the effect of Sanofi’s termination and the continuing economics and termination rights under the Spark agreement.
- Review the $21.0 million SVB loan’s interest-rate exposure, collateral package, covenants, default triggers and repayment schedule.
- Evaluate dilution from the 2017 PIPE, Spark equity issuances, stock options, warrants and the $50 million ATM program.
- Confirm future financing needs and whether the company can maintain development programs without additional equity, debt or collaboration funding.